Paris, France – May 2025 – Plantibodies proudly announces its graduation from the Endless Frontier Labs (EFL) program at NYU Stern School of Business, completing a transformative nine-month journey within the Life Sciences Track.
EFL is one of the world’s most selective startup accelerators, designed to fast-track the growth of science-based ventures by pairing them with leading investors, entrepreneurs, and industry experts. Plantibodies’ participation provided strategic guidance, global visibility, and direct access to U.S. biotech and pharma networks.
Throughout the program, Plantibodies refined its strategy, strengthened its fundraising readiness, and expanded international connections to advance its colon-targeted oral biologics platform.
“Graduating from EFL is a pivotal moment for us,” said Pierre Bauër, CEO and co-founder. “The insights and network we gained in New York will continue to shape our global development and partnerships as we push our innovation toward the clinic.”
This graduation marks a new phase for Plantibodies as it leverages its enhanced visibility and U.S. network to accelerate R&D collaborations and prepare for upcoming preclinical milestones.